bluebird bio, Inc. (BLE.F)
| Previous close | 15.90 |
| Open | 15.85 |
| Bid | 0.00 x 12000 |
| Ask | 0.00 x 12000 |
| Day's range | 15.85 - 15.90 |
| 52-week range | 15.31 - 49.99 |
| Volume | |
| Avg. volume | 103 |
| Market cap | 1.075B |
| Beta (5Y monthly) | 1.61 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.31 |
| Earnings date | 21 Feb 2022 - 25 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.80 |
- Business Wire
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
CAMBRIDGE, Mass., January 18, 2022--bluebird bio, Inc. (NASDAQ: BLUE) today announced that the US Food and Drug Administration (FDA) has extended the review period for the biologics licensing applications (BLA) for its lentiviral vector gene therapies – betibeglogene autotemcel (beti-cel) for β-thalassemia and elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD). The revised PDUFA goal dates for beti-cel and eli-cel are August 19, 2022 and September 16, 2022, respectively.
- Business Wire
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., January 11, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced planned updates to be presented at the 40th Annual J.P. Morgan Healthcare conference including 2022 program milestones and financial outlook.
- Business Wire
bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., January 05, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the virtual 40th Annual J.P. Morgan Healthcare Conference, Wednesday, January 12, at 3:45 p.m. ET.
